Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PN-101 in Refractory Polymyositis or Dermatomyositis
NCT04976140Phase 2Completed
- Sponsor
- Paean Biotechnology
- Start
- Dec 2021
- Primary completion
- Oct 2023
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of PN-101 in polymyositis (PM) and dermatomyositis (DM) (3 arms), sponsored by Paean Biotechnology. Primary endpoints: Dose Limiting Toxicity at 2 weeks and International Myositis And Clinical Studies group-Total Improvement Score at 12 weeks. Started Dec 2021; status: completed.
02
Drugs
PN-101
03
Conditions
polymyositis (PM)dermatomyositis (DM)
Beyond the preview
Go deeper on NCT04976140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04976140.